ALK enters into neffy® co-promotion agreement in the USA

ALK (ALKB.DC / OMX: ALK B) today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY) to co-promote the neffy^® adrenaline (epinephrine) nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% of all adrenaline auto-injector prescriptions in the USA.